•  
FN
Resources
  • PODCASTS
  • VIDEOS
SCROLL

FN RISK PORTAL

Assess your patient’s risk category (i.e. high, intermediate, low) of febrile neutropenia (FN) for more than 160 chemotherapy regimens

breast.png

Breast

cervical.png

Cervical

colorectal.png

Colorectal

esophageal_gastric.png

Esophageal / Gastric

multiple-myeloma.png

Multiple myeloma

non-hodgkin-s-lymphoma.png

Non-Hodgkin's lymphoma

non-small-cell-lung-and-small-cell-lung.png

Non-small-cell lung

ovarian.png

Ovarian

pancreas.png

Pancreatic

prostate.png

Prostate

non-small-cell-lung-and-small-cell-lung.png

Small-cell lung

soft-tissue-sarcoma.png

Soft tissue sarcoma

testicular.png

Testicular

uterine.png

Uterine

In addition, information is included for 18 common patient-specific risk factors that could potentially increase a patient’s chances of developing FN.

The FN Risk Web Portal is for educational background use only. It does not contain an exhaustive or complete list of regimens or other treatment options or risk factors and is not intended as medical advice, a clinical practice guideline, substitution for clinical judgment, or a recommendation on how to assess febrile neutropenia (FN) risk. All chemotherapy regimen and risk factor information should be confirmed independently.


Breast Cancer


Select a Regimen

 

Select Patient Risk Factors

Risk factors are independent of tumor type and regimen


Breast Cancer


REGIMEN RISK OF FN: -


Regimen References

COVID-19

National Comprehensive Cancer Network® (NCCN®). COVID-19 Resources: Supportive Care – Hematopoietic Growth Factors. NCCN. 2020 https://www.nccn.org/covid-19/pdf/HGF_COVID-19.pdf.*

*Referenced with permission from the National Comprehensive Cancer Network, Inc. © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed July 13, 2020. To view the most recent and complete version of the recommendations, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

- Information provided is on select patient risk factors associated with chemotherapy induced neutropenia based on national clinical practice guidelines or published literature. It does not contain an exhaustive or complete list of regimens or other treatment options or risk factors. It is not intended or to be viewed as medical advice, a clinical practice guideline, or a recommendation on how to assess febrile neutropenia (FN) risk. It does not substitute clinical judgment. All chemotherapy regimen and risk factor information should be confirmed independently.
- ICD-10-CM codes are from the ICD-10 Manual on the CMS website. Providers should contact each insurer to determine the appropriate codes for the services provided. The authors do not guarantee that use of any code(s) will ensure coverage or payment at any level. The information presented is for informational purposes only and is not intended to provide reimbursement or legal advice.
- The authors make no claims regarding the accuracy of the information contained herein.

Patient Risk Factors for FN in Addition to Chemotherapy Regimen and Cancer Type


RISK FACTOR references

  • None

Risk of chemotherapy was determined high as defined by NCCN Guidelines* and additional clinical data**

*NCCN defines FN risk of > 20% as high - NCCN Guidelines for Hematopoietic Growth Factors. Version 2.2020.

**Other clinical data considers FN risk of ≥ 17% as high - Vogel CL, et al. J Clin Oncol. 2005: PMID: 15718314

Risk of chemotherapy was determined intermediate as defined by NCCN Guidelines* and additional clinical data**

*NCCN defines FN risk of 10-20% as intermediate - NCCN Guidelines for Hematopoietic Growth Factors. Version 2.2020.

**Other clinical data considers FN risk of 10 to < 17% as intermediate - Vogel CL, et al. J Clin Oncol. 2005: PMID: 15718314

This information provided is on select chemotherapy regimens that are generally viewed based on national clinical practice guidelines or published literature to be associated with an intermediate or high risk of FN as well as information on select patient risk factors associated with chemotherapy induced FN according to national clinical practice guidelines or published literature. It is not intended or to be viewed as medical advice, a clinical practice guideline, or a recommendation on how to assess febrile neutropenia (FN) risk. It does not substitute clinical judgment. All chemotherapy regimen and risk factor information should be confirmed independently. The authors make no claims regarding the accuracy of the information contained in the portal.

DIGITAL RESOURCES

  • All
  • Video
  • Podcast

video-1.png

video-2.png

Coming Soon

Coming Soon

The portal includes information on select chemotherapy regimens that are generally viewed based on national clinical practice guidelines or published literature to be associated with low, intermediate, or high risk of FN as well as information on select patient risk factors associated with chemotherapy induced FN according to national clinical practice guidelines or published literature. By clicking 'Begin', I acknowledge that I have read and agree to the following:

  • The information provided in this portal is for the user's personal information and for educational use only. It is not intended or to be viewed as medical advice, a clinical practice guideline, or a recommendation on how to assess febrile neutropenia (FN) risk.
  • The portal includes information on select chemotherapy regimens that are generally viewed based on national clinical practice guidelines or published literature to be associated with low, intermediate or high risk of FN as well as information on select patient risk factors associated with chemotherapy induced FN according to national clinical practice guidelines or published literature. It does not contain an exhaustive or complete list of regimens or other treatment options or risk factors.
  • Medical professionals are learned experts responsible for all decisions in consultation with their patients and other resources they deem necessary to evaluate such risk and any potential treatment options. The information provided does not replace or substitute the exercise of independent clinical judgment.
  • All chemotherapy regimen and risk factor information should be confirmed independently.
  • Permissions for journal articles referenced in this portal must be obtained separately from the publishers.
  • The authors make no claims regarding the accuracy of the information contained herein.
BEGIN
Amgen Corporate Visit @amgen twitter feed Visit amgen’s youtube channel
Amgen.com Amgen MedInfo Privacy & Terms Your Cookie Preferences Careers
© 2020 Amgen Inc. All rights reserved.

  • Home
    Home
  • Cancers
    Cancers
  • Regimens
    Regimens
  • Digital Resources
    Digital Resources